Loading...
Found 21 results for chemotherapy
A listing of chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Testing the Addition of Chemotherapy Drug, Cisplatin, to Usual Radiation Therapy for Patients with Head and Neck Cancer
G
Greg Durm, MD
The purpose of this study is to compare two treatment approaches that are currently used after surgery for head and neck cancer. One approach is to administer radiation therapy alone. A second approach is to administer radiation therapy along with the chemotherapy drug, cisplatin.
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)
T
Tarah Ballinger, MD
This study will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) …
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
L
Lisa Landrum, MD, PhD, MS
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy …
NearWave optical molecular monitoring for predicting complete pathological response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer patients
T
Tarah Ballinger, MD
The purpose of this study is to assess the feasibility of the NearWave optical molecular monitoring system for monitoring therapy progression and predicting pathologic complete response (pCR) of breast cancer patients undergoing neoadjuvant chemotherapy (NAC). Interested in participating? For more information about this research study or other cancer-related clinical trials at …
A phase 2, randomised, multi-centre, open label trial to evaluate the safety and efficacy ofintravesical nadofaragene firadenovec alone or in combination with chemotherapy(gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with high-grade Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) (ABLE-22)
H
Hristos Kaimakliotis, MD
The pivotal phase 2 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and efficacy of intravesical instillation of nadofaragene firadenovec alone or in combination …
A Randomized Phase Ii/Iii Study of Docetaxel and Ramucirumab with or Without Cemiplimab (Regn2810) for Participants Previously Treated with Platinum-Based Chemotherapy and Immunotherapy for Stage Iv or Recurrent Non-Small Cell Lung Cancer (Lung-Map Non-Matched Sub-Study)
R
Rohan Maniar
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody …
Shortstop-Her2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage Her2+ Breast Cancer Who Achieve Pcr After Neoadjuvant Chemotherapy with Her2 Blockade
K
Kathy Miller, MD
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal …
Investigating the Temporal Relationship: Chemotherapy-Induced Peripheral Neuropathy in Children and Adolescents with Cancer
J
Jenny Belsky, DO
Cancer treatment can sometimes lead to the development of a condition called peripheral neuropathy. This is when your arms, hands, legs, and feet may tingle, like they are asleep, or cause pain. We want to look at characteristics that might predict who will develop this condition. Only eligible patients that …
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
J
Jessica Parker Metter
What is the purpose of this study?The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer …
A Phase II trial Evaluating Safety and Efficacy of Epcoritamab with Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
V
Varun Mittal
The goal of this study:Estimate complete remission (CR) rate per the Lugano classification with a combination of epcoritamab and GDP in subjects with relapsed large cell lymphoma.Estimate overall response rate (ORR) per the Lugano classification with a combination of epcoritamab and GDP in subjects with relapsed large cell lymphoma.Estimate duration …
Please choose between Voice or SMS based delivery of verification code
or